Adalimumab

In 2021, Humira — the blockbuster biologic that has for years been the highest grossing drug in the world — accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

Etanercept and adalimumab are both impactful at improving the health of patients with non-systemic juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

The FDA approved Idacio as a biosimilar to Humira, a TNF inhibitor with indications for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.

In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

Cigna Pharmacy announced that it will add adalimumab biosimilars as “preferred products” at the same price level as the originator Humira on its commercial formularies, according to a company press release.

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

PHILADELPHIA — An early switch from adalimumab to upadacitinib due to non-response demonstrated clinical improvement among patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Among patients with rheumatoid arthritis who had an inadequate response or intolerance to TNF inhibitors, upadacitinib demonstrated clinically meaningful and improved efficacy over 24 weeks, according to a post-hoc analysis.

PHILADELPHIA — In patients with psoriatic arthritis, upadacitinib showed greater improvement compared with both placebo and adalimumab as assessed by the Routine Assessment of Patient Index Data 3, or RAPID3, scores.

The American Gastroenterology Association recently spoke out about data that showed colonoscopy screening had a modest benefit in colorectal cancer.